Enochian

Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting

Retrieved on: 
Friday, June 23, 2023
Annual Meetings of the International Monetary Fund and the World Bank Group, Cancer, Infection, Annual report, Annual general meeting, Growth, Proxy, Security (finance), Holding company, Eastern Time Zone, Enochian

Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise that its 2023 Annual Stockholder Meeting (the “Annual Meeting”), which was scheduled to be held yesterday, June 22, 2023 at 12:00 p.m. Eastern Time, was convened and adjourned, without any business being conducted, due to the lack of the required quorum.

Key Points: 
  • Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise that its 2023 Annual Stockholder Meeting (the “Annual Meeting”), which was scheduled to be held yesterday, June 22, 2023 at 12:00 p.m. Eastern Time, was convened and adjourned, without any business being conducted, due to the lack of the required quorum.
  • To register to attend the virtual Annual Meeting, please visit http://www.viewproxy.com/enochianbio/2023/htype.asp before 11:59 PM EST on July 20, 2023.
  • This material may be deemed to be solicitation material in respect of the Adjourned Annual Meeting to be held on July 21, 2023.
  • In connection with the Annual Meeting, the Company filed a definitive proxy statement with the SEC on May 15, 2023.

Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review

Retrieved on: 
Thursday, June 8, 2023
Pancreatic cancer, Triple-negative breast cancer, US Foods, Human, Cancer immunology, University, Neoplasm, Enochian, Survival, New Drug Application, Cancer, Life expectancy, Mesothelioma, Mouse, UCLA, FDA, IND, Food, Pharmaceutical industry, Vaccine, Immunotherapy

Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company’s Pre-IND submission.

Key Points: 
  • Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company’s Pre-IND submission.
  • If successful, that would allow clinical trials to begin by the first half of 2024.
  • The Company’s proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors.
  • The initial studies have been conducted in a pancreatic cancer mouse model developed and published by Dr. Jewett’s laboratory.

Enochian BioSciences’ CEO Letter to Shareholders

Retrieved on: 
Monday, April 3, 2023
Survival rate, Pancreatic cancer, Injection, University, HIV, Neoplasm, Enochian, Drug discovery, Cancer, Head, Infection, Cell, Neck, Person, Trial of the century, US, MD, Platform, Mesothelioma, Mouse, Neurosurgery, UCLA, Safety, Medicine, Vaccine, Pharmaceutical industry, Medical imaging, Pediatrics, Microbiology, IND

The fact that we saw very similar highly statistically significant results across two independently conducted studies is particularly encouraging, indicating reproducibility of the findings.

Key Points: 
  • The fact that we saw very similar highly statistically significant results across two independently conducted studies is particularly encouraging, indicating reproducibility of the findings.
  • I am pleased to be able to provide shareholders with a summary of recent advances and what we believe is a promising future for the Company.
  • This was accomplished while substantially reducing operating costs – including, at my request, a decrease in my compensation as CEO - towards maximizing shareholder value.
  • We look forward to your continued support as we work towards life-saving scientific advances and a promising new future for the Company.

Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher

Retrieved on: 
Wednesday, March 29, 2023
Pancreatic cancer, US Foods, University, HIV, Drug discovery, Enochian, Survival, Hope, Disease, Immunotherapy, Life expectancy, UCLA, IND, Pancreatic tumor, Food, Vaccine, Pharmaceutical industry, Cancer

The results were part of an invited plenary lecture delivered by Dr. Jewett at the 8th Annual Innate Killer Summit in San Diego, California (relevant slides from the presentation can be viewed at: Presentation Excerpt--Innate Killer Summit_ENOB DC-11). The humanized mouse model is widely used to study cancer therapies that could potentially be applicable to human disease.

Key Points: 
  • The experiments demonstrated highly significant reductions in the weight and volume of pancreatic tumors following therapy with the Company’s proprietary technology combining cell-, gene- and immunotherapy.
  • Those results correlated with strong immune responses, indicating proof-of-concept of the way the technology was intended to act.
  • The humanized mouse model is widely used to study cancer therapies that could potentially be applicable to human disease.
  • Because of limited treatment options, life expectancy is very poor – approximately 10 percent survival at 5 years.

Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements

Retrieved on: 
Monday, March 13, 2023
Annual report, Lead, General counsel, Interim, Gilead Sciences, Science, Pharmaceutical industry, Enochian

Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements.

Key Points: 
  • Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements.
  • “I am very pleased that the Company is once again compliant with the NASDAQ listing requirements.
  • We have turned another page towards a promising future,” said Gregg Alton, former long-time General Counsel and Chief Compliance Officer and, later, Interim CEO of Gilead Sciences, and Lead Independent Board Member of Enochian BioSciences.
  • Dr. Mark Dybul, CEO of the Company, said, “Returning to full compliance is a significant accomplishment.

Investigation Alert UBER, CODX, ENOB, OM: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors’ Losses?

Retrieved on: 
Thursday, October 20, 2022
Risk, Uber, NYSE, NASDAQ, List, Food, Company, Marketing, Lists of schools in England, Safety, Disclosure, LLP, FDA, COVID-19, Ridesharing company, Pharmaceutical industry, Online shopping, Enochian

Johnson Fistel, LLP is investigating potential claims on behalf of Uber Technologies, Inc. (NYSE: UBER) against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Uber Technologies, Inc. (NYSE: UBER) against certain of its officers and directors.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Uber's business, operations, and compliance policies.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Co-Diagnostics, Inc. (Co-Dx or the Company) (NASDAQ: CODX) against certain of its officers and directors.
  • Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia.

DEADLINE ALERT for ENOB, WEBR, and CVNA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, September 26, 2022
Registration statement, Time, Suite, Twitter, Risk, Company, Investment, Lists of schools in England, Complaint, Law, Defendant, Documentation, GLOBE, Register, Mail, Holding company, Property management, Carvana, Enochian

LOS ANGELES, Sept. 26, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Sept. 26, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

ENOCHIAN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Enochian Biosciences, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, September 25, 2022
Class Action Lawsuit, Professional Services, Legal, Seraph, Central District, Risk, U.S. Department of Justice Office of Legislative Affairs, Coronavirus, Justice, LLC, Company, News, P.C, For Hire, Person, Office of Inspector General, U.S. Department of Health and Human Services, Lists of schools in England, Cancer, Hindenburg, Hepatitis B virus, Technology, HIV, Defendant, Jeanne Eagels, Science, SRI, Fraud, Court, NASDAQ, China Biologic Products, Telephone, District court, G-Technology, Hindenburg Research, Identity theft, Private investigator, Renewable energy, Pharmaceutical industry, Enochian

Investors have until September 26, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until September 26, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy.
  • On this news, Enochians stock price fell $2.17 per share, or 36.97%, to close at $3.70 per share on May 25, 2022.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Enochian Biosciences, Inc. (ENOB)

Retrieved on: 
Friday, September 23, 2022
Professional Services, Class Action Lawsuit, Research report, Time, The Wall Street Journal, Suite, Twitter, U.S. Department of Justice Office of Legislative Affairs, Justice, Company, News, FBI, Office of Inspector General, U.S. Department of Health and Human Services, Lists of schools in England, Hindenburg, Law, Defendant, Court, NASDAQ, Hindenburg Research, Pharmaceutical industry, Enochian

On May 25, 2022, the U.S. Department of Justice announced that Serhat Gumrukcu, the co-founder and inventor of Enochian, had been arrested in a murder-for-hire conspiracy.

Key Points: 
  • On May 25, 2022, the U.S. Department of Justice announced that Serhat Gumrukcu, the co-founder and inventor of Enochian, had been arrested in a murder-for-hire conspiracy.
  • On this news, the Companys shares fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022, on unusually heavy trading volume.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Edelson Lechtzin LLP Reminds Enochian Biosciences, Inc. Investors of the Impending Lead Plaintiff Deadline

Retrieved on: 
Thursday, September 22, 2022
Complaint, Felony, Central District, Coronavirus, U.S. Department of Justice Office of Legislative Affairs, Douglas v. U.S. District Court ex rel Talk America, Company, News, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, ENOB, LLP, Cancer, Lists of schools in England, Hepatitis B virus, HIV, NASDAQ, China Biologic Products, GLOBE, District court, Hindenburg Research, Online gambling, Pharmaceutical industry, Enochian

Investors who purchased Enochian during the Class Period have until September 26, 2022 to select counsel and move for appointment as a lead plaintiff.

Key Points: 
  • Investors who purchased Enochian during the Class Period have until September 26, 2022 to select counsel and move for appointment as a lead plaintiff.
  • The lead plaintiff acts as a representative for other class members in directing the litigation.
  • If you continue to hold Enochian shares and wish to discuss your legal options, please contact Edelson Lechtzin LLP, toll free at 1-844-696-7492, or by email at [email protected].
  • This news caused the price of Enochian stock to plummet an additional 28%, or $1.495 a share, to close at $3.77.